Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (27)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Hundscheid, R. D.L.
Right arrow Articles by Thomas, C. M.G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hundscheid, R. D.L.
Right arrow Articles by Thomas, C. M.G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 16, No. 3, 457-462, March 2001
© 2001 European Society of Human Reproduction and Embryology

Increased serum FSH in female fragile X premutation carriers with either regular menstrual cycles or on oral contraceptives

Rubin D.L. Hundscheid1,2, Didi D.M. Braat1, Lambertus A.L.M. Kiemeney3, Arie P.T. Smits2 and Chris M.G. Thomas1,4,5

1 Departments of Obstetrics and Gynaecology, 2 Human Genetics, 3 Epidemiology, and 4 Chemical Endocrinology, University Medical Centre Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands

Fragile X premutations are known to be a risk factor for diminished ovarian function at a relatively young age. We studied endocrine profiles of female fragile X family members (n = 79) at risk of premature ovarian failure (POF). Of these 79 women aged <40 years, 45 had menstrual cycles, and 34 were using oral contraceptives. Of the women with menstrual cycles, the premutation carriers had higher serum FSH concentrations than women who were not carrying the premutation. Even premutation carriers with regular cycles showed increased serum FSH concentrations. Moreover, premutation carriers using oral contraceptives also demonstrated increased serum FSH concentrations. Irrespective of whether oral contraceptives were used, a serum FSH concentration of >=15 IU/l was more common in the premutation carriers than in the other women. One premutation carrier using oral contraceptives had a serum FSH concentration of >40 IU/l, the threshold that defines POF. We confirmed that premutation carriers with menstrual cycles demonstrate premature ovarian dysfunction. However, we also found endocrine signs of unrecognized ovarian dysfunction in premutation carriers using oral contraceptives, despite endocrine alterations by oral contraceptives. Premutation carriers may have a poorer prognosis for future pregnancy, either achieved spontaneously or by assisted reproductive technology. We recommend that premutation carriers should be counselled not to wait too long if they wish to start a family.

Key words: diminished ovarian reserve/fragile X premutation/FSH/inhibin B/premature ovarian failure

5 To whom correspondence should be addressed at: Department of Chemical Endocrinology, University Medical Centre Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands. E-mail: C.Thomas{at}ace.azn.nl


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Hum ReprodHome page
J. Rohr, E.G. Allen, K. Charen, J. Giles, W. He, C. Dominguez, and S.L. Sherman
Anti-Mullerian hormone indicates early ovarian decline in fragile X mental retardation (FMR1) premutation carriers: a preliminary study
Hum. Reprod., May 1, 2008; 23(5): 1220 - 1225.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
K. J. McTavish, M. Jimenez, K. A. Walters, J. Spaliviero, N. P. Groome, A. P. Themmen, J. A. Visser, D. J. Handelsman, and C. M. Allan
Rising Follicle-Stimulating Hormone Levels with Age Accelerate Female Reproductive Failure
Endocrinology, September 1, 2007; 148(9): 4432 - 4439.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
E.G. Allen, A.K. Sullivan, M. Marcus, C. Small, C. Dominguez, M.P. Epstein, K. Charen, W. He, K.C. Taylor, and S.L. Sherman
Examination of reproductive aging milestones among women who carry the FMR1 premutation
Hum. Reprod., August 1, 2007; 22(8): 2142 - 2152.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
H. S. Kok, K. M. van Asselt, Y. T. van der Schouw, P. H.M. Peeters, and C. Wijmenga
Genetic studies to identify genes underlying menopausal age
Hum. Reprod. Update, September 1, 2005; 11(5): 483 - 493.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
A.K. Sullivan, M. Marcus, M.P. Epstein, E.G. Allen, A.E. Anido, J.J. Paquin, M. Yadav-Shah, and S.L. Sherman
Association of FMR1 repeat size with ovarian dysfunction
Hum. Reprod., February 1, 2005; 20(2): 402 - 412.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. K. Welt, P. C. Smith, and A. E. Taylor
Evidence of Early Ovarian Aging in Fragile X Premutation Carriers
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4569 - 4574.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
K. Gersak, H. Meden-Vrtovec, and B. Peterlin
Fragile X premutation in women with sporadic premature ovarian failure in Slovenia
Hum. Reprod., August 1, 2003; 18(8): 1637 - 1640.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
P. Platteau, K. Sermon, S. Seneca, A. Van Steirteghem, P. Devroey, and I. Liebaers
Preimplantation genetic diagnosis for fragile Xa syndrome: difficult but not impossible
Hum. Reprod., November 1, 2002; 17(11): 2807 - 2812.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.